Prevention and treatment of hypogonadism-associated bone loss and bone metastases by OPG-Fc in a model of mixed osteolytic/osteoblastic metastases

被引：0
|
作者：
Padalecki, S. S. [1 ]
Grubbs, B. [1 ]
Goins, B. [1 ]
Soundarajan, A. [1 ]
Mundy, G. R. [2 ]
Dougall, W. [3 ]
机构：
[1] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA
[2] VUMC, Nashville, TN USA
[3] Amgen Inc, Cambridge, MA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2007年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S311
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [31] Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening
    Aspenberg, Per
    Agholme, Fredrik
    Magnusson, Per
    Fahlgren, Anna
    BONE, 2011, 48 (02) : 225 - 230
  • [32] OPG-Fc Treatment in Growing Pigs Leads to Rapid Reductions in Bone Resorption Markers, Serum Calcium, and Bone Formation Markers
    Sipos, W.
    Zysset, P.
    Kostenuik, P.
    Mayrhofer, E.
    Bogdan, C.
    Rauner, M.
    Stolina, M.
    Dwyer, D.
    Sommerfeld-Stur, I.
    Pendl, G.
    Resch, H.
    Dall'Ara, E.
    Varga, P.
    Pietschmann, P.
    HORMONE AND METABOLIC RESEARCH, 2011, 43 (13) : 944 - 949
  • [33] Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss
    Dionisio, Maria Rita
    Mansinho, Andre
    Abreu, Catarina
    Cavaco-Silva, Joana
    Casimiro, Sandra
    Costa, Luis
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1114 - 1124
  • [34] Bone Metastases and Bone Loss Medical Treatment in Prostate Cancer Patients
    Safriadi, Ferry
    ACTA MEDICA INDONESIANA, 2013, 45 (01) : 76 - 80
  • [35] Antalgic treatment of pain associated with bone metastases
    Reale, C
    Turkiewicz, AM
    Luzi, M
    Reale, CA
    Bartolotta, G
    ANNALS OF ONCOLOGY, 1998, 9 : 51 - 51
  • [36] Antalgic treatment of pain associated with bone metastases
    Reale, C
    Turkiewicz, AM
    Reale, CA
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 1 - 11
  • [37] OSTEOLYTIC BONE METASTASES IN BREAST-CARCINOMA PATHOGENESIS, MORBIDITY AND BISPHOSPHONATE TREATMENT
    ELTE, JWF
    BIJVOET, OLM
    CLETON, FJ
    VANOOSTEROM, AT
    SLEEBOOM, HP
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (04): : 493 - 500
  • [38] Prostatic Acid Phosphatase Alters the RANKL/OPG System and Induces Osteoblastic Prostate Cancer Bone Metastases
    Kirschenbaum, Alexander
    Izadmehr, Sudeh
    Yao, Shen
    O'Connor-Chapman, Kieley L.
    Huang, Alan
    Gregoriades, Elias M.
    Yakar, Shoshana
    Levine, Alice C.
    ENDOCRINOLOGY, 2016, 157 (12) : 4526 - 4533
  • [39] Development and Validation of a Radiomics Model for Differentiating Bone Islands and Osteoblastic Bone Metastases at Abdominal CT
    Hong, Ji Hyun
    Jung, Joon-Yong
    Jo, Aram
    Nam, Yoonho
    Pak, Seongyong
    Lee, So-Yeon
    Park, Hyerim
    Lee, Seung Eun
    Kim, Sanghee
    RADIOLOGY, 2021, 299 (03) : 626 - 632
  • [40] A p38 MAP kinase inhibitor exacerbates osteolytic bone metastases due to breast and prostate cancers and has no effect on osteoblastic metastases
    Mohammad, K. S.
    Stebbins, E.
    Niewolna, M.
    McKenna, C. R.
    Peng, X.
    Higgins, L. S.
    Wong, D. H.
    Guise, T. A.
    BONE, 2010, 47 : S316 - S317
12345